利拉鲁肽对成人 2 型糖尿病患者 C 反应蛋白 (CRP) 的疗效和安全性：对对照试验进行GRADE评估的系统综述和剂量反应荟萃分析

IF 2.4 Q3 NUTRITION & DIETETICS PharmaNutrition Pub Date : 2024-09-18 DOI:10.1016/j.phanu.2024.100409

Nazanin Mozaffari , Mohammad Vesal Bideshki , Mohsen Mohammadi Sartang , Mehrdad Behzadi

{"title":"利拉鲁肽对成人 2 型糖尿病患者 C 反应蛋白 (CRP) 的疗效和安全性：对对照试验进行GRADE评估的系统综述和剂量反应荟萃分析","authors":"Nazanin Mozaffari , Mohammad Vesal Bideshki , Mohsen Mohammadi Sartang , Mehrdad Behzadi","doi":"10.1016/j.phanu.2024.100409","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Liraglutide (LRG) is an analog of glucagon-like-peptide-1 which has beneficial effects on controlling glycemic in diabetes patients. However, the effect of liraglutide on the C-reactive protein (CRP) was controversial in different studies. So, this study aimed to investigate the effect of LRG on CRP in adults with type 2 diabetes (T2DM).</p></div><div><h3>Methods</h3><p>Through March 2024, Web of Science, PubMed, and Scopus electronic databases were searched for pertinent studies. Calculation of 95 % confidence intervals (CIs) and mean differences was done using random effects model. Standard methods assessed dose-response, meta-regression, sensitivity, and publication bias. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to calculate evidence certainty.</p></div><div><h3>Results</h3><p>Finally, after reviewing 9 eligible studies with 10 arms including 1494 participants, a significant decrease in CRP levels was observed after treatment with LRG (WMD = −0.692 mg/L, 95 % CI: −1.01, −0.37, P<0.001). According to the results of the subgroup, LRG had greater effects in obese patients (Body mass index ≥30), high-quality studies, dosages >1.6 mg/d and durations ≥24 weeks. Linear (P<0.001) and non-linear (P <sub>dose-response</sub> =0.009) dose-response associations were observed between LRG dosages and CRP levels. According to the GRADE, evidence for CRP was high.</p></div><div><h3>Conclusions</h3><p>LRG had beneficial effects on CRP levels in adults with T2DM, especially in obese patients.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"30 ","pages":"Article 100409"},"PeriodicalIF":2.4000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled trials\",\"authors\":\"Nazanin Mozaffari , Mohammad Vesal Bideshki , Mohsen Mohammadi Sartang , Mehrdad Behzadi\",\"doi\":\"10.1016/j.phanu.2024.100409\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Liraglutide (LRG) is an analog of glucagon-like-peptide-1 which has beneficial effects on controlling glycemic in diabetes patients. However, the effect of liraglutide on the C-reactive protein (CRP) was controversial in different studies. So, this study aimed to investigate the effect of LRG on CRP in adults with type 2 diabetes (T2DM).</p></div><div><h3>Methods</h3><p>Through March 2024, Web of Science, PubMed, and Scopus electronic databases were searched for pertinent studies. Calculation of 95 % confidence intervals (CIs) and mean differences was done using random effects model. Standard methods assessed dose-response, meta-regression, sensitivity, and publication bias. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to calculate evidence certainty.</p></div><div><h3>Results</h3><p>Finally, after reviewing 9 eligible studies with 10 arms including 1494 participants, a significant decrease in CRP levels was observed after treatment with LRG (WMD = −0.692 mg/L, 95 % CI: −1.01, −0.37, P<0.001). According to the results of the subgroup, LRG had greater effects in obese patients (Body mass index ≥30), high-quality studies, dosages >1.6 mg/d and durations ≥24 weeks. Linear (P<0.001) and non-linear (P <sub>dose-response</sub> =0.009) dose-response associations were observed between LRG dosages and CRP levels. According to the GRADE, evidence for CRP was high.</p></div><div><h3>Conclusions</h3><p>LRG had beneficial effects on CRP levels in adults with T2DM, especially in obese patients.</p></div>\",\"PeriodicalId\":20049,\"journal\":{\"name\":\"PharmaNutrition\",\"volume\":\"30 \",\"pages\":\"Article 100409\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmaNutrition\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213434424000355\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmaNutrition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213434424000355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

摘要

背景利拉鲁肽（LRG）是胰高血糖素样肽-1的类似物，对控制糖尿病患者的血糖有好处。然而，不同研究对利拉鲁肽对C反应蛋白（CRP）的影响存在争议。因此，本研究旨在探讨利拉鲁肽对成人 2 型糖尿病（T2DM）患者 CRP 的影响。方法截至 2024 年 3 月，在 Web of Science、PubMed 和 Scopus 电子数据库中检索了相关研究。使用随机效应模型计算95%置信区间（CI）和平均差异。采用标准方法评估剂量反应、元回归、敏感性和发表偏倚。结果最终，在回顾了9项符合条件的研究，共10个研究臂，包括1494名参与者后，观察到LRG治疗后CRP水平显著下降（WMD = -0.692 mg/L，95 % CI：-1.01，-0.37，P<0.001）。根据亚组结果，LRG对肥胖患者（体重指数≥30）、高质量研究、剂量>1.6 mg/d、持续时间≥24周的疗效更好。LRG剂量与CRP水平之间存在线性（P<0.001）和非线性（P剂量-反应=0.009）剂量-反应关系。结论LRG对患有T2DM的成人，尤其是肥胖患者的CRP水平有益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled trials

Background

Liraglutide (LRG) is an analog of glucagon-like-peptide-1 which has beneficial effects on controlling glycemic in diabetes patients. However, the effect of liraglutide on the C-reactive protein (CRP) was controversial in different studies. So, this study aimed to investigate the effect of LRG on CRP in adults with type 2 diabetes (T2DM).

Methods

Through March 2024, Web of Science, PubMed, and Scopus electronic databases were searched for pertinent studies. Calculation of 95 % confidence intervals (CIs) and mean differences was done using random effects model. Standard methods assessed dose-response, meta-regression, sensitivity, and publication bias. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to calculate evidence certainty.

Results

Finally, after reviewing 9 eligible studies with 10 arms including 1494 participants, a significant decrease in CRP levels was observed after treatment with LRG (WMD = −0.692 mg/L, 95 % CI: −1.01, −0.37, P<0.001). According to the results of the subgroup, LRG had greater effects in obese patients (Body mass index ≥30), high-quality studies, dosages >1.6 mg/d and durations ≥24 weeks. Linear (P<0.001) and non-linear (P _{dose-response} =0.009) dose-response associations were observed between LRG dosages and CRP levels. According to the GRADE, evidence for CRP was high.